

# Ortho Clinical Diagnostics History

**1944:** Dr. Philip Levine, a pioneer in the field of hematology, joined Ortho Clinical Diagnostics to continue his breakthrough research into the mechanics of the Rh system in human blood. This marked the beginning of the company's commitment to diagnostic medicine. Among Dr. Levine's many contributions was research that led to the development of Rh Immune Globulin to protect Rh-negative women against isoimmunization, saving the lives of thousands of babies.

**1947:** Developed the first blood bank anti-D test for the

clinical market. This was a revolutionary advance in the burgeoning blood banking industry.

**1968:** Introduced RhoGAM® Rho(D) Immune Globulin (Human), the first drug developed to prevent Rh hemolytic disease of the newborn. This major milestone in the history of medicine established the company's reputation as a leader in the field of immunohematology.

**1977:** Introduced MICRhoGAM® Rho(D) Immune Globulin (Human), the first mini-dose.

**1978:** Introduced patented thin-film dry-slide technology, once again revolutionizing the field of diagnostics by providing clinical professionals with the means to receive high-quality results quickly, cleanly and economically

**1989:** Introduced the first test for the detection of antibodies to hepatitis C.

**1996:** Introduced the first test kit to screen blood for antigens to HIV-1, the virus that is responsible for the vast majority of AIDS cases in the U.S.

**1997:** Introduced the most advanced immunodiagnostic system available in the industry. The innovative VITROS® ECi Immunodiagnostic System allows labs to conduct more sensitive tests such as thyroid, fertility, anemia, endocrinology and cardiology with greater speed, accuracy and cost-effectiveness.

**1997:** Introduced the Ortho AutoVue® System, the first fully automated blood banking system in Europe.

**1997:** Introduced RhoGAM® Ultra-Filtered Rho(D) Immune Globulin (Human).

**1999:** Introduced the Ortho Summit™ System, the first fully automated blood and plasma screening system available in the U.S.

**1999:** Became one of the first diagnostic industry suppliers to offer contracted implementation services that can significantly reduce clinical laboratory costs through operational efficiencies and streamlined processes.

**1999:** Became one of the first diagnostic industry suppliers to offer contracted implementation services for operational efficiencies and streamlined processes.

**2000:** Released the HCV Core Antigen ELISA Test System—the first test commercially available for the direct detection of HCV core antigen in blood and plasma, a marker of early infection in hepatitis C-infected individuals.

**2000:** Established Advanced Cellular and Diagnostic Systems (now Veridex), an independently managed franchise focused on bringing high value diagnostic, monitoring and screening solutions to cancer and other disease states such as CNS and cardiovascular.



**2001:** Introduced RhoGAM® Ultra-Filtered Rho(D) Immune Globulin (Human) in pre-filled syringes with safety shields in U.S., the first company to do so.

**2001:** Became the first diagnostic company to receive U.S. FDA approval for automated random access hepatitis tests, on the VITROS® ECi Immunodiagnostic System.

**2001:** Developed Ortho trak-C™, the world's first branded Total HCV Core Antigen test designed to provide reliable measures of HCV viremia that will lead to improvements in the

management of patients with HCV infection.

**2002:** Acquired Micro Typing Systems of Pompano Beach, Florida, the manufacturer of the ID-Micro Typing System™ (ID-MTS) used in hospitals and donor centers to help to ensure safe and effective blood transfusions.

**2003:** Launched ORTHO ProVue® Analyzer, the first fully automated Immunohematology system for use with the ID-Micro Typing System™ (ID-MTS) Gel Test in North America.

**2004:** Launched VITROS® ECiQ Immunodiagnostic System and the Ortho AUTOVUE® Innova Analyzer.

**2004:** Launched VITROS® 5, 1 FS Chemistry System, raising industry standards for ease-of-use, integrity of results and operational efficiency.

**2005:** Launched VITROS® 350 Chemistry System.

**2006:** Launched the first FDA licensed test to screen blood donations for exposure to Chagas' disease.

**2007:** Launched VITROS®, Troponin I ES Assay used along with other cardiac tests, to help diagnose a heart attack and to detect and evaluate heart injury.

**2009:** OCD launches FETALSCREEN™ II Fetal Maternal Hemorrhage Screening Test, a simple, qualitative test that detects D (Rho) positive fetal red blood cells in the maternal circulation of pregnant Rh-negative women

**2009:** OCD enters into an agreement with Avioq, Inc. to develop and commercialize a test in the U.S. to screen for antibodies to human

T-lymphotropic virus (HTLV) type I and II

OCD gains approval of the VITROS® HBeAg assay – a test for the Hepatitis B “e” antigen – for use on the VITROS® ECi/ECiQ Immunodiagnostic Systems in the United States

**2011:** OCD unveiled its new brand campaign, “Bloodlines,” inspired by the people behind the science of transfusion medicine –

the blood bankers who help protect precious life on the journey between blood donor and blood recipient.

**2012:** The Avioq<sup>8745</sup> HTLV-I/II Microelisa System assay becomes available, a new test developed by OCD in partnership with Avioq, Inc. to screen blood and organ donations for antibodies to human T-lymphotropic virus (HTLV) type I and II